Head of the section: Dr.. Rob Wolthuis
ONCOGENETICS
Exploiting Advanced Genomic Techniques to Improve Cancer Care
Our research is directed at functionally characterizing genes involved in hereditary cancer predispositions, and exploring their roles in general cancer biological mechanisms. Research findings are translated into future clinical applications whenever possible. In addition to contributing to DNA diagnostics, we also strive to advance personalized treatment of cancer and the early detection of cancer, especially via non-invasive approaches such as liquid biopsies.
We study the molecular pathways of the pediatric cancer retinoblastoma, hereditary kidney cancer, and cohesinopathies. Recently, we started investigating a new research line aimed at understanding how cancer cells may exploit meiosis-associated DNA repair pathways.
“The Oncogenetics section investigates genes and genetic networks that contribute to hereditary and sporadic cancers.” – Dr. Rob Wolthuis
CRISPR gene editing
To achieve these aims, we perform studies at basic mechanistic, translational, and diagnostic levels, employing state-of-the art genomics technologies including RNA and DNA sequencing, live cell fluorescence imaging, and CRISPR technology. With CRISPR, we are engineering human cell models for genome-wide functional genomics. To maximally exploit the possibilities of the new CRISPR technique, a new initiative, the CRISPR Expertise Center
, has been established with support of the Cancer Center Amsterdam and Amsterdam UMC.
For more information, see our website.
English 
Dutch